Affimed is a clinical-stage immuno-oncology company focused on discovering and developing targeted cancer immunotherapies. Co.'s main candidate, AFM13, is an innate cell engager (ICE®) designed for the treatment of certain CD30-positive malignancies, including for both Hodgkin lymphoma and certain non-Hodgkin lymphomas. Co.'s second candidate, AFM24, is designed to address limitations, such as toxicities or treatment resistance, associated with existing therapeutic anti-epidermal growth factor receptor monoclonal antibodies. Co.'s third wholly-owned ICE® molecule, AFM28, was developed from its ROCK® platform and is designed to bind to CD123, an established target in myeloid malignancies. We show 8 historical shares outstanding datapoints in our coverage of AFMD's shares outstanding history.
Understanding the changing numbers of AFMD shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AFMD versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AFMD by allowing them to research AFMD shares outstanding history
as well as any other stock in our coverage universe. |
Free AFMD Email Alerts:
Video: Shares Outstanding Importance
